Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum WELL Health Technologies Corp T.WELL.DB


Primary Symbol: T.WELL Alternate Symbol(s):  WHTCF

WELL Health Technologies Corp. is a practitioner-focused digital healthcare company. The Company develops technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. Its business units include Canadian Patient Services, WELL Health USA Patient Services and SaaS and Technology Services. WELL Health USA Patient and... see more

TSX:WELL - Post Discussion

View:
Post by retiredcf on Mar 22, 2024 8:24am

Two Responses

The first one was their earnings assessment followed by reaction to the conference call. GLTA

EPS of 5c beat estimates of 4.8c; revenue of $213.2M beat estimates by 4%. EBITDA of $30.75M beat estimates by 2%. Revenue was a record, up 48%. Canadian operations (clinics and platforms) performed very well. Guidance of sales of $950M+ and EBITDA of $125M+ were both above current estimates. Organic growth was a solid 15%. WELL also announced some cost-cutting measures to be implemented. The stock is down, but we can't really explain why. It was a good quarter, with good growth and a good outlook. Here are some other comments below: WELL Health Technologies' 4Q results continued its streak of beating consensus forecasts for over four years, "aided by strong performances in its Canadian business where Adjusted EBITDA increased 39% y/y in F2023." TD analyst David Kwan says that as well as the strong results, the new revenue guidance for the year which raises targets by 6% to 8% "implies acceleration in growth," compared with 2023. "We believe this strong result should help support a continued rebound in its share price". 

----------------------------------------------------------------------


First, on the decline, we would note that the stock rose 39c in the three days prior to the release, so the 10% drop Thursday really only equates to a 4c drop for the week so far. Some investors no doubt got worried about lower margins and growth, but the market 'should' move on expectations and we would have assumed these were in analysts' forecasts already. Guidance was increased and calls for 25% growth but investors seem skeptical this will be achieved for some reason. We like the 15% organic growth. The conference call did not add too much, and management was confident. There was some discussion on a weaker Q1, but this is mostly seasonality, and again, we would have expected analysts/investors to be aware of this seasonality. Nothing in the call gave us any additional concerns. (5iResearch)
Comment by retiredcf on Mar 24, 2024 7:54am
Friday morning response to a disgruntled subscriber. GLTA You initially said that results were good and it appeared from your answer that there were no negatives. But the stock was taking a big hit. Then new questions came in and you responded that there were some negatives (eg decrease in margins, net income and cash flow). Obviously these are important as sellers stepped in and continue today ...more